Literature DB >> 25269943

Engineered antibody therapies coming of age for aging brains.

Anne Messer1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25269943      PMCID： PMC4428410          DOI： 10.1038/mt.2014.170

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  Targeted delivery of proteins across the blood-brain barrier.

Authors:  Brian J Spencer; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 2.  Aging as an event of proteostasis collapse.

Authors:  Rebecca C Taylor; Andrew Dillin
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

3.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

4.  Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.

Authors:  Hedieh Barkhordarian; Sharareh Emadi; Philip Schulz; Michael R Sierks
Journal:  Protein Eng Des Sel       Date:  2006-09-19       Impact factor: 1.650

5.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

6.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

Review 7.  Intrabodies as neuroprotective therapeutics.

Authors:  Anne Messer; Shubhada N Joshi
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease.

Authors:  Brian Spencer; Robert A Marr; Ryan Gindi; Rewati Potkar; Sarah Michael; Anthony Adame; Edward Rockenstein; Inder M Verma; Eliezer Masliah
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

9.  Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.

Authors:  Brian Spencer; Sharareh Emadi; Paula Desplats; Simona Eleuteri; Sarah Michael; Kori Kosberg; Jay Shen; Edward Rockenstein; Christina Patrick; Anthony Adame; Tania Gonzalez; Michael Sierks; Eliezer Masliah
Journal:  Mol Ther       Date:  2014-07-10       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.